RSK-IN-2

• Description :

  RSK-IN-2 (Compound 3e) is a RSK inhibitor, with IC50 s of 37.89 nM (RSK2), 30.78 nM (RSK1), 20.51 nM (RSK3), 91.28 nM (RSK4) . RSK-IN-2 inhibits tumor cell proliferation, induces apoptosis and causes cell cycle arrest in the G2/M phase[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Ribosomal S6 Kinase (RSK)

• Related Pathways :

  Apoptosis; MAPK/ERK Pathway

• Field of Research :

  Cancer

• Purity :

  99.32

• Solubility :

  DMSO : 35 mg/mL (ultrasonic)

• Smiles :

  CN1CCN(C2=CC(OC)=C(NC3=NC(NC4=CC=CC=C4C(NCCO)=O)=C(Cl)C=N3)C=C2)CC1

• Molecular Formula :

  C25H30ClN7O3

• Molecular Weight :

  512.00

• References & Citations :

  [1]Han C, et al. Discovery of 2,4-dianilinopyrimidine derivatives as novel p90 ribosomal S6 protein kinase (RSK) inhibitors. Eur J Med Chem. 2025 Jul 5;291:117590.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  RSK2; RSK3; RSK4

• CAS Number :

  [3011713-80-4]